Terns Pharmaceuticals, Inc. (TERN) Stock Analysis

Terns Pharmaceuticals, Inc. (TERN) Healthcare & Pipeline Overview

Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company specializing in developing small-molecule therapeutics for non-alcoholic steatohepatitis (NASH) and obesity. With a pipeline of single-agent and combination therapies, Terns is positioned to address the growing unmet needs in the liver disease and metabolic disorder markets.

What Is the Investment Thesis for TERN?

Terns Pharmaceuticals presents a notable research candidate due to its focused pipeline targeting NASH and obesity, diseases with significant unmet medical needs. The company's lead candidate, TERN-101, is in Phase IIa clinical trials, offering a potential near-term value inflection point. Positive clinical data from ongoing trials for TERN-101, TERN-201, and TERN-501 could serve as major catalysts. The market capitalization of $4.77B reflects investor confidence in the company's potential. However, the inherent risks associated with clinical-stage biopharmaceutical companies, including trial failures and regulatory hurdles, must be considered. Successful development and commercialization of its drug candidates could drive substantial long-term value.

Based on FMP financials and quantitative analysis

TERN Key Highlights

TERN-101 is in Phase IIa clinical trial for the treatment of NASH, representing a potential near-term value inflection point.

• TERN-201, a vascular adhesion protein-1 inhibitor, is in Phase Ib clinical trial for the treatment of NASH.
• TERN-501, a thyroid hormone receptor beta agonist, is in Phase I clinical trial for the treatment of NASH.
• TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program, is intended for oral administration for NASH and metabolic diseases, such as obesity.
• The company has a market capitalization of $4.77B, reflecting investor confidence in its pipeline and potential.

Who Are TERN's Competitors?

TERN is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance This table mixes two scoring engines — compare a number only with others carrying the same tag.

What Are TERN's Key Strengths?

Focused pipeline targeting NASH and obesity.

• Clinical-stage drug candidates with potential for near-term value inflection points.
• Experienced management team.
• Proprietary small-molecule drug candidates.

What Are TERN's Weaknesses?

Reliance on clinical trial success.

• Limited financial resources compared to larger pharmaceutical companies.
• High risk of clinical trial failures.
• Dependence on regulatory approvals.

What Could Drive TERN Stock Higher?

TERN-101 Phase IIa clinical trial data readout expected in late 2026.

• TERN-201 Phase Ib clinical trial for NASH.
• TERN-501 Phase I clinical trial for NASH.

What Are the Key Risks for TERN?

Negative return on equity (-20.0%) — the business is not currently generating profit on shareholder capital.

• Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
• Insider selling — insiders were net sellers of roughly $71.0M recently.
• Clinical trial failures for TERN-101, TERN-201, and TERN-501.
• Regulatory hurdles in obtaining approval for drug candidates.
• Competition from other companies developing NASH and obesity therapies.
• Patent expirations on key drug candidates.

What Are the Growth Opportunities for TERN?

• TERN-101 Phase IIa Clinical Trial Success: Positive results from the ongoing Phase IIa clinical trial of TERN-101 for NASH could significantly increase the company's valuation. Timeline: Data readout expected in late 2026.
• TERN-201 Phase Ib Clinical Trial Advancement: Advancing TERN-201, a vascular adhesion protein-1 inhibitor, through Phase Ib clinical trials for NASH presents a growth opportunity. Positive outcomes could lead to further development and potential commercialization. The VAP-1 inhibition mechanism offers a novel approach to treating NASH. Timeline: Ongoing clinical trials with potential for advancement in 2027.
• TERN-501 Phase I Clinical Trial Progression: The progression of TERN-501, a thyroid hormone receptor beta agonist, through Phase I clinical trials for NASH represents a growth opportunity. Successful early-stage trials could pave the way for further development and potential partnerships. Thyroid hormone receptor beta agonists have shown promise in treating NASH. Timeline: Ongoing Phase I trials with potential for Phase II initiation in 2027.
• TERN-601 Oral GLP-1 Receptor Agonist Development: The development of TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program, for oral administration in treating NASH and obesity presents a significant growth opportunity. Oral GLP-1 agonists offer a convenient alternative to injectable therapies. The obesity market is substantial and growing. Timeline: Preclinical development with potential for clinical trials in 2027-2028.
• Strategic Partnerships and Licensing Agreements: Terns Pharmaceuticals could pursue strategic partnerships and licensing agreements to expand its pipeline and accelerate the development and commercialization of its drug candidates. Collaborations with larger pharmaceutical companies could provide access to resources and expertise. Timeline: Ongoing efforts with potential for announcements in 2026-2027.

What Are TERN's Competitive Advantages?

• Proprietary small-molecule drug candidates.
• Focus on NASH and obesity therapeutics.
• Clinical-stage pipeline with potential for near-term value inflection points.
• Experienced management team with expertise in drug development.

What Does TERN Do?

Terns Pharmaceuticals, Inc., founded in 2016 and headquartered in Foster City, California, is a clinical-stage biopharmaceutical company dedicated to discovering and developing innovative therapies for the treatment of chronic liver diseases, specifically non-alcoholic steatohepatitis (NASH), and obesity. The company's approach involves creating small-molecule single-agent and combination therapy candidates designed to target the underlying mechanisms of these complex diseases. Terns' pipeline features a diverse range of drug candidates, including TERN-101, a liver-distributed and non-bile acid farnesoid X receptor (FXR) agonist currently in Phase IIa clinical trials for NASH. Additionally, Terns is developing TERN-201, a vascular adhesion protein-1 (VAP-1) inhibitor, which is in Phase Ib clinical trials, also for NASH. The company is also advancing TERN-501, a thyroid hormone receptor beta (THR-β) agonist with enhanced liver distribution and metabolic stability, currently in Phase I clinical trials for NASH. Furthermore, Terns is working on TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program intended for oral administration to treat NASH and metabolic diseases like obesity. Terns Pharmaceuticals aims to provide effective treatment options for patients suffering from NASH and obesity, addressing a significant unmet medical need in the healthcare landscape.

What Products and Services Does TERN Offer?

• Develop small-molecule single-agent therapies for NASH and obesity.
• Develop combination therapies for NASH and obesity.
• Conduct clinical trials to evaluate the safety and efficacy of their drug candidates.
• Focus on liver-distributed drug candidates.
• Target specific receptors and proteins involved in NASH and obesity.
• Develop orally administered therapies for NASH and obesity.

How Does TERN Make Money?

• Develop and out-license drug candidates.
• Generate revenue through milestone payments and royalties.
• Focus on NASH and obesity therapeutics.
• Advance drug candidates through clinical trials.

What Industry Does TERN Operate In?

Terns Pharmaceuticals operates within the biotechnology industry, specifically targeting the rapidly growing market for NASH and obesity treatments. The NASH market is expected to experience substantial growth due to the increasing prevalence of obesity and related metabolic disorders. Competition in this space is intense, with numerous companies developing novel therapies. Terns differentiates itself through its focus on small-molecule single-agent and combination therapies, aiming to provide effective and convenient treatment options.

Who Are TERN's Key Customers?

• Pharmaceutical companies seeking to license novel NASH and obesity therapies.
• Patients suffering from NASH and obesity.
• Healthcare providers treating patients with NASH and obesity.

Return on equity for Terns Pharmaceuticals, Inc. stands at -20.0%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -9.4%, showing how much profit it generates from its asset base. Its free cash flow yield is -1.7%, a gauge of the cash the business throws off relative to its market value. A current ratio of 62.41 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -2.0%, the inverse of the P/E and a quick read on earnings relative to price.

Terns Pharmaceuticals, Inc. (TERN) Valuation Context

Valued at $4.77B, TERN is classified as a mid-cap stock.

Company Profile

Terns Pharmaceuticals, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Foster City, US. The company is led by CEO Amy L. Burroughs. TERN has traded publicly since 2021.

Terns Pharmaceuticals, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.

Wall Street analysts project Terns Pharmaceuticals, Inc. revenue of about $960K for fiscal 2026, with EPS near $-1.16. The estimate reflects 7 contributing analysts.

Over the past six months, Terns Pharmaceuticals, Inc. insiders filed 58 SEC Form 4 transactions — 57 sales and 1 purchases. On net that is roughly 5.9M shares disposed (about $71.0M), a signal worth weighing alongside the fundamentals.

TERN Financials

TERN Latest News

Terns Pharmaceuticals, Inc. Healthcare Stock: Key Questions Answered

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources